Cargando…
Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness
INTRODUCTION: The presence of cardiovascular (CV) risk factors and CV disease in patients with chronic obstructive pulmonary disease (COPD) leads to worse outcomes. A number of tools are currently available to stratify the risk of adverse outcomes in these patients with COPD. This post hoc analysis...
Autores principales: | Horne, Benjamin D, Ali, Rehan, Midwinter, Dawn, Scott-Wilson, Catherine, Crim, Courtney, Miller, Bruce E, Rubin, David B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802087/ https://www.ncbi.nlm.nih.gov/pubmed/33447025 http://dx.doi.org/10.2147/COPD.S279645 |
Ejemplares similares
-
The Summit Score Stratifies Mortality and Morbidity in Chronic Obstructive Pulmonary Disease
por: Horne, Benjamin D, et al.
Publicado: (2020) -
A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD
por: Bhatt, Surya P, et al.
Publicado: (2017) -
Adjudication of cardiovascular events in patients with chronic
obstructive pulmonary disease: SUMMIT trial
por: Wise, Robert A, et al.
Publicado: (2020) -
Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial
por: Byrd, James Brian, et al.
Publicado: (2018) -
FEV(1) Minimum Important Difference versus Minimal Detectable Difference? In Search of the Unicorn
por: Crim, Courtney, et al.
Publicado: (2021)